title: Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
authors.forename: Efstathios
authors.initials: E
authors.lastname: Rallis
authors.forename: Constantinos D
authors.initials: CD
authors.lastname: Verros
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; C055085:calcipotriene; C117268:pimecrolimus; D016572:Cyclosporine; D000069285:Infliximab; D000069549:Ustekinumab; D002117:Calcitriol; D000068879:Adalimumab; D017255:Acitretin; D000068800:Etanercept; D016559:Tacrolimus; D008727:Methotrexate